Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Depreciation & Amortization - Total (2019 - 2025)

Sunshine Biopharma (SBFM) has disclosed Depreciation & Amortization - Total for 7 consecutive years, with $95821.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Depreciation & Amortization - Total rose 48.27% year-over-year to $95821.0, compared with a TTM value of $221550.0 through Sep 2025, up 36.74%, and an annual FY2024 reading of $146518.0, up 32.35% over the prior year.
  • Depreciation & Amortization - Total was $95821.0 for Q3 2025 at Sunshine Biopharma, up from $72533.0 in the prior quarter.
  • Across five years, Depreciation & Amortization - Total topped out at $95821.0 in Q3 2025 and bottomed at -$11597.0 in Q4 2024.
  • Average Depreciation & Amortization - Total over 5 years is $27168.8, with a median of $9179.5 recorded in 2022.
  • The sharpest move saw Depreciation & Amortization - Total soared 4616.1% in 2023, then tumbled 397.05% in 2024.
  • Year by year, Depreciation & Amortization - Total stood at $3184.0 in 2021, then skyrocketed by 353.99% to $14455.0 in 2022, then plummeted by 72.99% to $3904.0 in 2023, then crashed by 397.05% to -$11597.0 in 2024, then surged by 926.26% to $95821.0 in 2025.
  • Business Quant data shows Depreciation & Amortization - Total for SBFM at $95821.0 in Q3 2025, $72533.0 in Q2 2025, and $64793.0 in Q1 2025.